Adalimumab time to discontinuation Kaplan–Meier curves in rheumatology pooled indications and rheumatoid arthritis—Prospective PSP versus prospective non-PSP.
figure
posted on 2024-06-13, 17:48 authored by Graeme Jones, Miriam Calao, Jakob Begun, Shirley Sin, Mahsa H. Kouhkamari, Elisa Young, Pablo Fernández-Peñas, Alan Watts, Andrew J. ÖstörPrimary Analysis Sets. Analyses weighted by the inverse probability of treatment weighting (IPTW). S1A) Rheumatology pooled Indications (RA, AS, PsA). S1B) Rheumatoid Arthritis.
(TIF)
History
Usage metrics
Categories
Keywords
services australia 10pharmaceutical benefit schememonth persistence ratesaustralian adult patients616 &# 821128 &# 8211patient support programobservational study evaluated68 ], p563 ], ppatients initiating adalimumaboptimal adalimumab persistence), psoriatic arthritispsp cohorts ).prospective psp cohortuc ),study suggestsrheumatoid arthritishealthcare supportadalimumab pspsincluded ).5304 ).001 ).structured psppsp cohortprospective pspxlink ">uc indicationstreatment weightingsponsor companyseptember 2019primary endpointpbs datasetmay 2018march 2009less likelyjanuary 2009january 2007inverse probabilityhidradenitis suppurativaextracting datadecember 2010december 2008april 2007
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC